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HPV16 DNA is often integrated in cancers, disrupting the E1 or E2 genes. E2 can repress the E6/E7 promoter, but other models have been
proposed to explain why integration promotes malignant progression. E1 and E2 are required for viral replication, and so genetic analysis of their
role in transcriptional regulation is complex. Therefore, we developed an extrachromosomal vector containing HPV16 to undertake a genetic
analysis of the E1 and E2 genes. We demonstrate that the E2 protein is primarily a transcriptional repressor when expressed from the virus.
Furthermore, repression requires both the transactivation function of E2 and specific binding of E2 to the LCR. We find no evidence that the E1
protein directly modulates HPV16 gene expression. However, certain E1 mutations modulated transcription indirectly by altering splicing of E2
mRNA species. These data provide important insight into which E1 and E2 functions are optimal targets for anti-viral therapies.
Published by Elsevier Inc.Keywords: HPV; Papillomavirus; Replication; Transcription; E1; E2; RepressionMost papillomaviruses induce benign epithelial lesions.
However, a specific subset of viruses are associated with
cancer, particularly that of the uterine cervix. HPV-associated
carcinomas no longer differentiate, nor produce viral
particles, and invariably express the viral E6 and E7 proteins.
One role of E6 and E7 is to induce differentiating epithelial
cells to enter S-phase so that viral DNA amplification can
take place. The E7 protein does this by inactivating the
cellular protein, pRb (Münger et al., 1989). The resulting
conflicting signals of cell cycle progression and differentia-
tion activate p53, which signals cells to undergo apoptosis or
growth arrest (Demers et al., 1994). The E6 protein disrupts
p53 function by targeting it for degradation (Scheffner et al.,
1990). In a subset of “high risk” viruses, deregulation of E6
and E7 gene expression can lead to genomic instability and
carcinogenesis.
In most cervical cancers, papillomavirus DNA is found
integrated into cellular chromosomes (Schwarz et al., 1985;
Boshart et al., 1984; Yee et al., 1985). This integration event⁎ Corresponding author. Fax: +1 301 480 1497.
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step in malignant progression. However, as yet, no single model
has been established to explain this observation. The E1 and E2
proteins are important for transcriptional regulation, replication
and segregation of viral DNA. E2 can repress the promoter that
expresses the E6 and E7 genes, and so disruption of the E2 gene
is postulated to increase expression of E6 and E7 (Thierry and
Yaniv, 1987; Tan et al., 1992, 1994). A similar phenomenon
might occur with inactivation of the E1 gene as E1 can repress
BPV-1 transcription (Sandler et al., 1993; Le Moal et al., 1994).
E6 and E7 gene expression can also be regulated by mRNA
stability and an element that confers instability has been
identified in the 3′ untranslated region of HPV16 mRNAs.
Integration of the viral genome can remove this element
resulting in increased stability of E6 and E7 mRNAs (Jeon and
Lambert, 1995). Additionally, E2-TA may have growth
inhibitory properties that are independent of E2-mediated
regulation of the E6 and E7 promoter. E2-TA can induce
growth arrest and apoptosis in HPV-negative cells, and so
inactivation of the E2 gene may release cell growth inhibition
by E2 and be intrinsically important to malignant progression
(Webster et al., 2000). Clearly, further studies are required to
understand how disruption of E1 and E2 can lead to genomic
instability and carcinogenesis.
Fig. 1. Diagram of the episomal vector, pEP16. (A) pEP16 contains the early
genes of HPV16, the EBVorigin of replication (oriP), the EBNA-1 gene and the
histidinol dehydrogenase gene. (B) DNA replication assay. HFKs were
transfected with pEP16 vectors and cells containing plasmids selected with
histidinol. After 22 days selection, low molecular weight DNA was extracted
and digested with DpnI. DpnI-resistant DNA was assessed by real-time PCR.
The DNA amount shown was that measured from 1/6000th of a 10-cm plate of
cells. pEP16 E2-N and E1-C contain translational termination linkers in E2 and
E1, respectively.
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E1 and E2 genes in the background of the virus because their
inactivation results in a replication-defective genome that
integrates into the cellular chromosomes. To circumvent this,
we have constructed a series of episomal expression vectors that
contain the “high-risk” HPV16 regulatory region and early
genes, the EBV EBNA-1 gene and oriP replication origin and a
selectable marker. These chimeric plasmids can replicate
episomally in human keratinocytes independent of HPV E1
and E2 genes.
It is well established that E2 can repress the E6 and E7
promoter (reviewed in McBride et al., 1998), but the only direct
evidence that E1 can function as a transcriptional repressor is in
BPV-1 (Le Moal et al., 1994; Sandler et al., 1993; Ferran and
McBride, 1998). In the HPV16 genome, mutation of either gene
increases cellular proliferation (Romanczuk and Howley, 1992),
which could indicate that E1 and E2 function as a complex to
repress E6 and E7 expression. In support of this model, E1 and
E2 bind cooperatively to the replication origin, which is located
just upstream from the P97 promoter. To clarify the role of E1
and E2 in the regulation of expression of the E6 and E7 genes,
we have generated specific mutations that disrupt E1 and E2
DNA binding sites and specific functions of E1 and E2 proteins
(complex formation, DNA binding, transactivation, replication,
and ATPase activities). The effect of these mutations on E6/E7
gene expression has been measured by quantitative real-time
PCR. This enables us to measure relative levels of HPV16 early
RNAs very accurately and also allows us to distinguish among
different spliced transcripts.
In the short-term assays presented here, we confirm that,
when expressed from the viral genome, E2 is primarily a
repressor of the P97 promoter; this repression involves E2
binding sites 1, 2, and 3, and both the DNA binding and
transactivation functions of E2. We find no evidence that P97 is
strongly activated by E2. We also demonstrate that the E1
protein plays no direct role in the regulation of the P97
promoter, and any change in P97 activity is mediated indirectly
through changes in the splicing and expression of E2 messages.
Results
EBV-based vector allows replication in the absence of either
E1 or E2 protein
To develop a chimeric HPV genome that could replicate
independently from E1 and E2 protein functions, the LCR and
early region of the HPV16 genome were cloned into the EBV
based vector, pEP8 (Fig. 1A). This vector replicates as an
extrachromosomal element by virtue of the EBVoriP replication
origin and the EBNA1 protein, and it can be maintained in cells
by selection for the histidinol resistance gene. To determine
whether this plasmid could replicate in the absence of the E1 or
E2 proteins, translation termination linkers were inserted into
either the E1 or E2 genes. The E1-CTTL truncates the E1 protein
after residue 616 and the E2 TTL results in truncation at amino
acid 56. The resulting plasmids were transfected into primary
human foreskin keratinocytes (HFKs), and cells containing themwere selected with histidinol. Episomal replication was assessed
after 22 days by analysis of extrachromosomal low molecular
weight DNA. Residual, unreplicated, input DNAwas cleaved by
digestion with DpnI and resistant, replicated DNA was
quantitated using real-time PCR (Fig. 1B). For this analysis, a
fragment containing nucleotides 3459 to 3581, which spans the
DpnI site at nucleotide 3481, was amplified. No significant
differences in levels of replicated DNA were observed among
the different plasmids, indicating that the vectors can replicate in
the absence of either E1 or E2 protein. This result also showed
that replication from these vectors was dominated by oriP and
EBNA1 and was not influenced by the presence of an HPV
origin.
The HPV16 early gene transcription and splicing pattern is not
changed by the pEP vector
In the pEP vector, expression of the HPV16 genes is
regulated by viral promoter and enhancer sequences. However,
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sequences, the pattern and levels of HPV16 early transcripts
expressed from the pEP vector were analyzed to ensure that the
relative abundance and splicing patterns were similar to those
expressed from the HPV16 genome. Primers were used to
specifically detect RNA species containing the E7 gene, the E6
gene (both exon I and the unspliced E6 transcript), E6*I and
E6*II species and the E2 gene, and are shown in Fig. 2A and
Table 1. RNA isolated from primary human keratinocytes
transfected with pEP16E2-N and selected for 3 months in
histidinol was compared with RNA from the cervical
carcinoma-derived cell line, Caski and two subclones of the
W12 cervical keratinocyte cell line, 20861 and 20863, which
contain integrated and episomal HPV16 genomes, respectively
(Fig. 2B). RNAwas also prepared from primary human foreskinFig. 2. HPV transcription and splicing from pEP16 plasmids is very similar to
that of the HPV16 genome. (A) Major HPV16 RNA species (Baker and Calef,
1996). The primers used to detect spliced and unspliced transcripts are indicated.
Note that splicing of the HPV16 early region results in multiple combinations of
the upper and lower three splicing events. (B) Comparison of transcription/
splicing pattern observed with transfected episomal vectors and a variety of
HPV16 expressing cell lines. The transcription/splicing pattern was assessed by
real-time QRT-PCR, and the amount of each RNA species was calculated using
the standard curve method. For the E2-N sample, RNAwas isolated from HFKs
transfected with pEP16E2-N after 3-month selection with histidinol.keratinocytes immortalized with the E6 and E7 expressing
retrovirus, pLXSN-E6E7 (Halbert et al., 1991) and from 293
cells transfected with p1059, a vector expressing E6 and E7
from the SV40 early promoter (Phelps et al., 1988). The amount
of each RNA species was assessed by real-time quantitative RT-
PCR and is shown in Fig. 2B as copy number detected in cDNA
prepared from 50 ng of RNA.
The amount of HPV16 RNAwas highest in cells expressing
E6 and E7 from the pLXSN retrovirus, but notably, the vast
majority of this RNA was unspliced. High levels of HPV16
early region RNAwere also expressed from the SV40 promoter
in 293 cells but, in contrast to all other samples, the E2
transcripts were higher than those of E7, indicating aberrant
promoter or splice site usage. However, the pattern and levels of
RNA species from the W12 20861, 20863, Caski and pEP16E2-
N cells were very similar. Integration of the HPV16 genome in
Caski and 20861 cells did not result in a change in splicing
patterns although, as has been observed previously, more
transcription was observed overall (Jeon and Lambert, 1995;
Jeon et al., 1995). Thus, the transcription and splicing pattern of
the HPV16 early region is very similar when expressed from the
pEP episomal vector or from the entire viral genome.
Both DNA binding and transactivation functions of E2 are
required for repression of HPV16 early gene transcription
The E1 and/or E2 genes are disrupted by integration in most
cervical carcinomas, and this has led to the hypothesis that E2
(and perhaps E1) regulates expression of E6 and E7 from the
P97 promoter. In addition, disruption of the E1 or E2 open
reading frames leads to an increase in viral immortalization
capacity (Romanczuk and Howley, 1992). It has been clearly
established that the E2 protein can repress transcription from the
HPV early region (Hou et al., 2000; Bouvard et al., 1994;
Demeret et al., 1997; Steger and Corbach, 1997; Romanczuk et
al., 1990; Tan et al., 1992). However, most studies have used
reporter plasmids to assess P97 function and/or used E2 protein
expressed from heterologous promoters and sometimes from a
different papillomavirus (e.g., BPV1). To understand specifi-
cally which E1 and E2 functions are required to regulate
expression of the E6 and E7 early region, we have introduced
very specific E1 and E2 mutations into the pEP16 vector and
analyzed the effect on HPV16 early region transcription in
short-term, transient assays.
To address which functions of E2 affect transcription of the
HPV16 early genes in the background of the viral genome, we
generated mutations that disrupted specific functions of E2 (Fig.
3A). Point mutations that eliminated DNA binding (R302K/
R304K) (McBride and Myers, 1997), transactivation (R37A,
I73A, or R37A/I73A) (Sakai et al., 1996), replication and E1
interaction (E39A) (Sakai et al., 1996; Abbate et al., 2004), or
replication and DNA binding (E39A/R302K/R304K) functions
were generated in the pEP16M plasmid by site-directed
mutagenesis. In addition, a translation termination linker was
inserted at nucleotide position 2712 (after residue 56); this
should eliminate all E2 functions (E2-N). The plasmids
containing the mutated HPV16 early region were transfected
Table 1
Real time QRT-PCR primers
mRNA Primer names Positions Sequences
HPV16 E7
E7 AM715 (sense) 689–708 GACAAGCAGAACCGGACAGA
E7 AM716 (antisense) 760–741 ACCGAAGCGTAGAGTCACAC
E7563 AM1123 (sense) 563–586 TGCATGGAGATACACCTACATTGC
E7649 AM1124 (antisense) 649–620 CATTTAATTGCTCATAACAGTAGAGATCAG
E6US AM713 (sense) 379–397 CAACAAACCGTTGTGTGAT
E6US AM714 (antisense) 540–522 CGTGTTCTTGATGATCTGC
E6*I oCCB-396 (sense) 208–226, 409–411 ACAGTTACTGCGACGTGAGATG
E6*I oCCB-350 (antisense) 445–428 TTCTTCAGGACACAGTGG
E6*II oCCB-345 (sense) 211–226, 526–528 GTTACTGCGACGTGAGATC
E6*II oCCB-351 (antisense) 586–568 GCAATGTAGGTGTATCTCC
E6 Exon1 oJMD-15 (sense) 152–171 ACAGAGCTGCAAACAACTAT
E6 Exon1 oJMD-16 (antisense) 204–185 TTGCAGTACACACATTCTAA
E2 AM771 (sense) 3302–3321 GTATGGGAAGTTCATGCGGG
E2 AM772 (antisense) 3381–3359 TCAGGAGAGGATACTTCGTTGCT
E2 880^2709 AM1126 (sense) 866–880, 2709–2711 TGGCTGATCCTGCAGGACG
E2 880^2709 AM1127 (antisense) 2778–2755 AAACGTTGGCAAAGAGTCTCCAT
E1^E4 AM1132 (sense) 866–880, 3358–3361 TGGCTGATCCTGCAGCAGC
E1^E4 AM1133 (antisense) 3440–3422 AGGCGACGGCTTTGGTATG
E2 880^2582 AM1128 866–880, 2582–2585 TGGCTGATCCTGCAGATTC
E2 880^2582 AM1129 2706–2680 TGAGAA AAAGGATTTCCAGTTCTTATC
E8^E2C AM1154 (sense) 1281–1302, 3358–3360 GGAAACTCAGCAGATGTTACAGCAG
E8^E2C AM1135 3418–3404 CGCGGCGGAGTGGTT
E1 AM1023 (sense) 1252–1271 GAAGACAGCGGGTATGGCA
E1 AM1024 (antisense) 1308–1282 TTCTACCTGTAACATCTGCTGAGTTTC
His D AM781 (sense) 3026–3044 CGCTGGTAATCGCATCCAC
His D AM782 (antisense) 3131–3111 ACCAAAGATTTAGCGCAGTGC
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expression was assessed by real-time QRT-PCR (Fig. 3B). To
adjust for differences in transfection efficiency, RNA encoded
by the histidinol dehydrogenase gene was also assessed and
used to normalize levels of all RNA species. Each experiment
was repeated at least three times, and each RNA sample was
analyzed in triplicate. A longer term study analyzing the effect
of these mutations on HPV16-mediated keratinocyte immortal-
ization will be published later.
Results are presented for both unspliced E7 transcripts,
which probably more accurately reflect levels of transcription
and the E6*I spliced mRNA species, since detection of spliced
mRNA species is inherently more specific than unspliced
species. In the short-term experiments, the E6*I and E7 RNA
species were present at similar levels. The E2-N mutation
resulted in an increase in both transcripts, consistent with the
previously described role of E2 as a transcriptional repressor. In
the absence of the E2 protein, the E6/E7 transcripts were present
at levels three fold higher than wild type. The E2 DNA binding
mutation, R302K/R304K, resulted in a similar increase in the
levels of HPV transcripts indicating that E2 binding to the LCR
is important for repression of transcription from P97. The
R37A, I73A, and R37A/I73A mutations, which have previously
been shown to be important for the transactivation function of
E2 (Sakai et al., 1996), also resulted in a 2-fold increase in E6/
E7 gene transcription. These proteins retain the ability to bind to
the LCR but do not repress transcription; therefore, the
transactivation function of E2 is also, at least partially, required
for repression. The E39A mutation has been shown to affect the
replication function of E2 by disrupting its ability to interactwith E1 (Sakai et al., 1996). This mutation did not affect HPV16
early gene transcription, showing that E1/E2 complex formation
(and therefore cooperative binding to the origin region) was not
required for transcriptional repression.
Several other promoters have been mapped to the E6/E7
region. Since E7 transcripts were measured using primers that
amplified the region between nt 689 and 760, it is possible that
transcripts initiating from the late promoter at P670 were also
detected. To rule out this possibility, primers were designed to
amplify a region of E7 that is upstream of P670 (nt 563 to 649).
No difference in the level of E7 transcripts was observed
between primer sets confirming that the late promoter was not
active under these cellular culture conditions (data not shown).
Recently, a novel promoter has been identified at nucleotide 542
(Rosenstierne et al., 2003). To determine whether expression
from the P542 promoter significantly contributed to E7 mRNA
levels, we compared RNA amounts using E7 and E6ex1
primers, which amplify a region between the P97 and P542
promoters (nt 152–204). This did not result in significantly
higher levels of RNA compared to the E7 primers, indicating
that P542 was also not significant in this analysis (data not
shown).
The E1 protein does not directly regulate transcription of the
HPV16 early region
To investigate whether the E1 protein regulates E6 and E7
expression, pEP vectors were generated containing the HPV16
genome with E1 mutations. The E1 open reading frame was
disrupted by a TTL after residue 149 (E1-N) or residue 616 (E1-
Fig. 4. E6*I and E7 mRNA levels expressed from pEP16 plasmids with
mutations in the E1 gene. (A) Schematic representations of E1 mutations and
functions. (B) Mutations in E1 binding site in origin. The arrows represent the
E1 binding sites (Chen and Stenlund, 2001). Nucleotide substitutions are
presented below the sequences. (C) Gene expression profile of HFK cells
transfected with pEP16 plasmids containing E1 mutations. Real-time RT-PCR
was performed after 2 days of transfection PCR, and the amount of each RNA
species was calculated using the standard curve method and normalized to
expression of the histidinol dehydrogenase gene.
Fig. 3. E6*I and E7 mRNA levels expressed from pEP16 plasmids with
mutations in the E2 gene. (A) Schematic representation of E2 mutations. (B)
Transcription/Splicing pattern and levels of early gene expression as measured at
2 days after transfection of HFKs with the designated plasmids. Gene expression
was assessed by real-time RT-PCR and the amount of each RNA species was
calculated using the standard curve method and normalized to expression of the
histidinol dehydrogenase gene.
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motif of E1 (K483A) (White et al., 2001), the DNA binding of
E1 (K230A/S231A) (Auster and Joshua-Tor, 2004; Gonzalez et
al., 2000; Woytek et al., 2001) or both ATPase and DNA
binding functions (K230A/S231A/K483A) (Fig. 4A). Muta-
tions were also generated in the E1 binding sites in the
replication origin (E1BSM2 and E1BSM4) (Fig. 4B) (Chen and
Stenlund, 2001).
The pEP plasmids were transfected into HFKs and RNA
was prepared two days later and assessed by real-time QRT-
PCR (Fig. 4C). As seen in Fig. 3, similar levels of the E6*I and
E7 RNA species were expressed. The overall levels and
patterns of expression of HPV16 RNA were similar to wild
type in each sample with the exception of the E1-C TTL, which
showed higher levels of overall viral transcription. However,
there was no increase in viral transcripts in cells transfected
with plasmid containing the E1-N. Clearly, if the increase in
RNA expression was due to the absence of the E1 protein, then
both truncation mutations should have a similar phenotype.
This phenotype could be the result of a partially functional,
truncated E1 protein, or it could be due to disruption of a cis-
element in the viral genome. We noted that in the E1-C
mutation, the TTL was inserted just after the E2 splice acceptor
(nt 2709), and therefore, this mutation could affect splicing and
expression of E2 and release the repression of P97 transcription
by E2.Insertion of TTL at position 2712 in the E1 ORF disrupts
splicing of an 880^2709 RNA species and reduces E2
expression
In HPV-positive cells, there are several RNA species
encoded by the E2 ORF. The E1^E4 (880^3358) RNA species
is most abundant compared with other alternatively spliced
RNA species. Two different spliced species (880^2709 and
880^2582) have been predicted to express the E2 protein
(Sherman and Alloul, 1992). And finally, a shorter repressor
form of the E2 protein, E8^E2C, is transcribed from a
1302^3358 spliced transcript. This protein can repress tran-
scription and extrachromosomal replication, and this repressive
function requires the E8 portion of the protein (Lambert et al.,
1987; Stubenrauch et al., 2001; Zobel et al., 2003).
To determine whether the insertion of a TTL at position 2712
specifically disrupts splicing of an 880^2709 RNA species (or
34 E. Soeda et al. / Virology 351 (2006) 29–41other RNA species), RT-PCR primers overlapping these splice
junctions (Fig. 5A) were designed. The relative abundance of
alternatively spliced E2 transcripts was assessed in RNA
prepared from HFKs transfected with either wt, E2-N, E1-C
or E1-N (Fig. 5B). Only very low levels of the 880^2582
mRNA species were observed suggesting that the majority of
the E2 protein is translated from the 880^2709 RNA species.
The E2-N and E1-N samples contained 1.8 and 1.3 times,
respectively, more of the E2 880^2709 species compared with
wt, consistent with an overall increase in early region
expression in the absence of E2. However, this species was
reduced drastically (10-fold) in the E1-C sample showing that
insertion of TTL had disrupted splicing of the 880^2709
species. Presumably, lack of splicing at this site resulted in
greatly decreased E2 protein expression with a concomitant
increase in P97 expression. Thus, mutations in the E1 protein
had no direct effect on expression of the HPV16 early region.
Both unspliced E2 and E1^E4 880^3358 species were also
analyzed. The E2-N and E1-C mutations resulted in 2.5- and
2.1-fold increases in the levels of the E1^E4 880^3358 species
compared with that of wt, consistent with a general increase in
early gene expression in the absence of the E2 protein. These
species seem to be regulated in a manner similar to the
880^2582 and 880^2709 RNAs, indicating that they are likely
initiated at the E2-regulated P97 promoter.Fig. 5. Variation in E2 mRNA transcripts expressed from the pEP16 plasmids with t
spliced and unspliced RNA species containing the E2 open reading frame (Sher
indicated. (B) The amounts of each E2 RNA species expressed from pEP16 plasm
species was calculated using the standard curve method and normalized to expresThe levels of the E8^E2C RNA species were also assessed in
the wt, E2-N, E1-C or E1-N RNA samples, as shown in Fig. 5B.
Notably, the levels of this RNA species showed a decrease with
all three mutations. This could indicate that E2 activates
expression of E8^E2C RNA species as we have shown that the
E2-N and E1-C mutations eliminate E2 expression. However,
the E1-N mutation, which does not affect E2 levels, also gives
rise to reduced E8^E2C expression. Notably, the TTL in E1-N is
at position 1311, just 9 nucleotides downstream from the 1302
splice donor. Thus, it is possible that the presence of the TTL
decreases splicing of the 1302^3358 E8^E2C transcript. The
different expression pattern of this transcript suggests that it
does not originate from the P97 promoter. Primers were also
used to analyze mRNA species from the E1 region. E1 mRNA
species, as detected by primers that amplified nucleotides 1252
to 1308, were present at similar levels to those of the unspliced
E2 mRNA species. Furthermore, these RNA species appeared
to be regulated in a similar manner, suggesting that they
originated from the same promoter (data not shown).
E2 functions as a transcriptional repressor in HFKs
Transcription from the P97 promoter is modulated by
interaction of the E2 protein with the four specific E2 binding
sites in the LCR (Romanczuk et al., 1990). E2 binds to each ofranslational termination linkers in the E1 and E2 genes. (A) Diagram of known
man and Alloul, 1992). RT-PCR primers specific for each RNA species are
ids with TTL mutations in E1 and E2 are shown. The amount of each RNA
sion of the histidinol dehydrogenase gene.
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binding sites are predicted to mediate transcriptional activation
or repression (Fig. 6A). The promoter proximal sites 1 and
2, which overlap essential Sp1 and TFIID binding sites,
have medium affinity for E2 binding and were shown to be
most important for E2-mediated repression of the P97
promoter (Tan et al., 1994). Binding site 3 contributes to
repression, but the mechanism of this repression is not
known (Thierry and Howley, 1991). E2 occupancy of
binding site 4 has been shown to activate transcription
under conditions in which all other binding sites are
disrupted (Romanczuk et al., 1990).
To test the contribution of each of the E2-binding sites on
regulation of viral transcription in the context of the entire
early region, mutations were generated that eliminated
individual E2 binding sites (pEP16-432x, -43x1, -4x21, and
-x321), combinations of two binding sites (pEP16-43xx, -4xx1,
and -4x2x), or the three promoter proximal sites (pEP16-4xxx),
as shown in Fig. 6B. Transcription from the early region was
assessed by measuring the levels of the E7 and E6*I RNA
species.
Mutation of individual E2 binding sites had only minimal
effect on E7 and E6*I expression. Mutation of E2 binding site 2
(43x1), which overlaps the Sp1 binding site, was the only
individual E2 binding site mutation that increased the levels of
the E7 and E6*I transcripts (Fig. 6C). Mutation of two or moreFig. 6. Effect of E2 binding site mutations on expression of the E6*I and E7 RNAs. (A
site, the TATA box and the start site of the P97 promoter. (B) The individual E2 bin
binding site, with mutated sites represented by closed boxes. The mutations in eac
accgaaatcggt to accgaaatcAgt; site 3, accgttttgggt to aTTgttttgggt; site 4; accgaattcgg
expression was assessed in HFKs transfected with pEP plasmids containing E2 bindin
and E7 RNAwas calculated using a standard curve. The value for each sample was n
the same plasmid.E2 binding sites mutations (-43xx, -4xxx, -4xx1, and -4x2x)
further alleviated E2-mediated repression. Although E2 binding
site one, proximal to the promoter, was still intact, pEP16-4xx1
expressed the same level of transcripts as pEP16-4xxx,
indicating that E2 binding sites 2 and 3 are important for
repression. Mutation of binding site 4 in pEP16-x321 had no
effect on transcription.
Expression of the E2 protein in trans enhances the regulatory
effect of the E2 binding sites
One caveat in the analysis of the effect of the E2 binding site
mutations in the background of the entire HPV early region is
that changes in activity of the P97 promoter resulting from these
mutations will in turn affect expression of the E2 protein itself,
so complicating the analysis. To eliminate this complication, the
pEP16 plasmids with the E2 binding site mutations were
cotransfected with an expression vector for the HPV16 E2
protein. This plasmid, CMV-E2, expresses E2 from the CMV
promoter and results in E2 expression that is in great excess to
that expressed from the early region (Del Vecchio et al., 1992).
Measurements of E2 RNA species showed that cotransfection
with the CMV-E2 plasmid resulted in a 39-fold increase in
unspliced E2 expressed from the cotransfected plasmid (data
not shown). However, as expected, there was no increase in the
levels of the spliced E2 species as they could not be expressed) Sequence of theW12 LCR showing the position of the E2 binding sites, the Sp1
ding site mutations are indicated for each plasmid. Each box represents an E2
h site were generated as follows: site 1, accgaaaccggt to acTgaaaccggt; site 2,
t to accgaattcTTt. Mutated nucleotides are in upper case letters. (C) E6*I gene
g mutations. RNAwas prepared 2 days posttransfection and the amount of E6*I
ormalized relative to the level of histidinol dehydrogenase RNA expressed from
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should eliminate effects due to variations in the level of the
endogenously expressed E2 protein and accentuate effects of
the E2 binding site mutations of the P97 promoter. The effect of
excess E2 expression on transcription from P97 was assessed by
measuring the level of the E6*I RNA species (Fig. 7).
Cotransfection with the pCMV empty vector had minimal
effect on E6*I expression from the E2 DNA binding site
mutation plasmids (Fig. 7). However, expression of HPV16 E2
in trans from the CMV-E2 plasmid decreased levels of the E6*I
transcript expressed from the wild-type pEP16 plasmid up to 2-
fold. Therefore, as predicted, the P97 promoter is not fully
repressed by endogenously expressed amounts of E2 protein.
However, cotransfection of the E2 expression vector decreased
the E6*I species 5-fold from the pEP16 E2-N genome, which
did not express a functional endogenous E2 protein. Coexpres-
sion of the E2 protein decreased the level of E6*I expression
from each of the genomes that retained an intact binding site 1
and to a lesser extent binding site 2. Plasmids containing
mutations that disrupted both E2BS1 and 2 (-43xx and -4xxx)
were no longer able to be repressed, consistent with previous
findings (Romanczuk et al., 1990). Plasmid -4xxx with binding
sites 1, 2, and 3 mutated expressed even higher levels of the
E6*I message than -43xx, both in the presence and absence of
E2, indicating that site 3 might also contribute to repression of
the P97 promoter.
It has been proposed that E2 binding to E2BS4 activates
transcription at low levels of E2 protein (Demeret et al., 1997).
In the pEP16 episomal plasmids, we have seen no strong
evidence that this site is responsible for either repression or
activation of the P97 promoter, in the presence of endoge-
nously or co expressed E2 protein, suggesting that binding site
4 does not contribute to the regulation of this promoter.
Mutation of this site does not greatly affect the level of E6*I
transcripts in the presence or absence of excess E2, suggestingFig. 7. Expression of E2 in trans represses the P97 promoter activity in pEP16
through the E2 binding sites. The series of pEP plasmids containing mutations in
the E2 binding sites were cotransfected with 1ug pCMV vector or pCMV-
HPV16E2. RNAwas prepared 2 days posttransfection, and the amount of E6*I
RNA was calculated using a standard curve. The value for each sample was
normalized relative to the level of histidinol dehydrogenase RNA expressed
from the same plasmid.that E2BS4 does not contribute to E2-mediated activation of
this promoter.
Discussion
In this study, we have analyzed the role of the E1 and E2
proteins on regulation of HPV16 early gene transcription.
Because the E1 and E2 proteins are responsible for viral DNA
replication, we developed an episomal vector that allowed us to
study the phenotype of E1 and E2 mutations in the background
of a replicating genome. In the experiments presented here, we
have analyzed the effect of these mutations in short-term assays
of viral transcription. However, this system can also be used for
long-term experiments to study the role of chromatin in
regulation of viral gene expression and to determine which E1
and E2 mutations result in HPV16 genomes with enhanced
immortalization capacity.
There were two concerns about studying HPV transcription
in a chimeric episomal vector. One concern was that the vector
contained two potential replication origins, which might lead to
interference of replication. However, this did not seem to be a
problem. The oriP origin was dominant, and no differences in
replication levels were observed in the presence or absence of
E1 and E2 proteins. We also made a series of double mutations
containing the K483A ATPase mutation, which by itself had no
effect on transcription but should eliminate any HPV replica-
tion, in combination with the E2 gene mutations presented here
(data not shown). The addition of the E1 K483A mutation had
no effect on the transcription patterns of the HPV16 early
region, indicating that replication was not influencing tran-
scription. Furthermore, the experiments presented here were
carried out shortly after transfection when replication of the
input plasmid would have little consequence.
Our second concern was that enhancer or promoter
elements in the non-HPV portion of the plasmid could
influence HPV transcription either by modulating HPV
promoters or by generating read-through transcripts that
could influence transcription in either a sense or antisense
direction. However, these concerns were also unfounded. The
vector portion of the pEP16 plasmid was quite transcriptionally
active; the levels of RNA expressed from the histidinol
dehydrogenase gene were approximately 100 to 200 times
greater than that of the E7 gene. However, there was no
evidence that this affected transcription from the HPV region.
We postulate that the presence of the entire LCR upstream
from the P97 promoter acts to insulate transcriptional effects
from sequences upstream in the plasmid, as it likely does in the
entire HPV16 genome.
Many types of vectors have been used to study regulation of
the HPV16 early region. We demonstrate here that valid
transcription and splicing patterns are only observed when the
HPV mRNAs are expressed from the HPV promoter/enhancer
region. The use of retroviruses or heterologous promoters and
enhancers to express the HPV genes does not result in authentic
levels or patterns of transcription. Similar conclusions about
splicing of the E6 and E7 transcripts have been made by Zheng
et al., who have demonstrated that the distance between the
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splicing. HPV16 E6E7 pre-mRNA takes advantage of its small
cap-proximal exon to confer efficient splicing for better E7
expression, whereas the longer exon resulting from expression
from the LXSN retroviruses decreases splicing of the E6*I
message (Zheng et al., 2004). We have also noted that
expression of the BPV1 E2-TR protein (presumably from the
P3080 promoter) in E2-TA expression vectors depends on
which heterologous promoter/enhancer is upstream from the
entire E2 open reading frame (unpublished data).
Earlier studies indicated that the papillomavirus E1 protein
might regulate transcription. Demeret et al. (1998) demonstrat-
ed that the HPV18 E1 protein can act as a transcriptional
activator protein by interaction with the E2 protein (Demeret et
al., 1998), and there is evidence that the BPV1 E1 protein can
both activate (Parker et al., 2000) and repress (Le Moal et al.,
1994; Ferran and McBride, 1998; Sandler et al., 1993)
transcription. It is possible that variations in the reporters, cell
lines, and protein expression levels contribute to these
observations. In this study, we find no effect of E1 mutations
on transcription from the HPV16 early region in short-term
assays, with the exception of the E1-C TTL, which we have
shown alters expression of the E2 gene. It is possible that more
subtle effects of E1 regulation might become more obvious in
long-term assays when the HPV sequences are packaged in
chromatin. Certainly, Romanczuk and Howley have shown that
disruption of the E1 ORF in the background of the HPV16
genome leads to increases in HPV16 immortalization capacity
(Romanczuk and Howley, 1992). The p16-Nt plasmid used in
that study is the same as the E1-N mutation used in our study.
We observed no alleviation in transcriptional repression with
this mutation, but a decrease in the level of the RNA species for
the E8^E2C transcriptional repressor was observed. Whether
this decrease, or other mechanisms, contribute to the observed
increase in immortalization activity observed with HPV16 E1
mutants remains to be determined.
As expected, abrogation of DNA binding of the E2 protein to
the LCR increased transcription from the P97 promoter.
Mutations of either the DNA binding function of the E2 protein
or the E2 binding sites in LCR alleviated P97 E2-mediated
repression. However, mutations in the transactivation function
of E2 (R37A, I73A, and R37A/I73A) also relieved repression
even though these proteins retain the ability to bind DNA.
Nishimura et al. and Goodwin et al. have demonstrated that
HPV16 E2 and BPV1 E2, respectively, require the transactiva-
tion function to repress E6/E7 expression from the HPV18 P105
promoter in HeLa cells (Nishimura et al., 2000; Goodwin et al.,
1998). Furthermore, Nishimura demonstrated using in vivo
footprinting that transactivation defective HPV16 E2 proteins,
R37A and I73A were actually unable to bind to the P105
promoter proximal E2 binding sites in HeLa cells (Nishimura et
al., 2000). Hou et al. have also demonstrated that E2 does not
simply displace TBP from the TATA box but functions as an
active repressor at steps after TATA recognition by TBP (Hou et
al., 2000). Therefore, the ability to bind DNA in vitro is not
sufficient for DNA binding and transcriptional repression in
vivo. The E2 protein is known to interact with both chromatinmodifying and remodeling factors, and these interactions are
likely required to enable E2 to access the promoter sequences as
well as to activate transcription (Steger et al., 2001; Muller et
al., 2002; Lee et al., 2002; Peng et al., 2000). Our study
confirms these observations and shows that the transactivation
function of E2 is required for full repression of the P97
promoter when expressed from the authentic HPV16 genome in
human keratinocytes.
The experiments presented here also show that the
magnitude of E2 regulation of the P97 promoter is not
great. Fig. 7 demonstrates that the difference between a fully
repressed P97 promoter (pEP16 wt cotransfected with CMV-
E2) and a fully derepressed P97 promoter (E2-N with CMV
vector) is only 5- to 7-fold. HPV transcription is regulated
mainly by cellular transcription factors, and the E2 protein
may simply fine-tune this regulation. However, the experi-
ments were carried out at early times after transfection. In
longer term experiments, E2 might have more substantial
effects in alleviating chromatin-mediated repression. The
experiments presented were carried out in monolayer
keratinocyte culture, which represent the undifferentiated
cells of a papilloma. The pEP16 plasmid would be extremely
useful to determine the role of the E2 protein in late viral gene
expression.
At first glance, the results presented here appear to be in
opposition with a study published by Bechtold et al. who
showed that E2 was unable to repress transcription from the
episomal HPV16 genome in W12 cells (Bechtold et al., 2003).
The most likely explanation for the differences observed
between our study and that of Bechtold et al. is that in the
study presented here our episomal vector is transiently
expressed and less likely to be susceptible to chromatin-
mediated transcriptional repression compared to the long-term
replicating HPV16 genomes replicating in the W12 cells. It is
likely that there will be differences in regulation of HPV
transcription after the pEP16 vector has replicated over many
cell divisions, and this vector will be invaluable for under-
standing how transcriptional regulation can change in different
circumstances, such as after long-term replication or in
differentiating keratinocytes.
The results obtained with the E1-C TTL mutation highlight
the care that must be taken in designing and interpreting the
phenotype of mutations in the small and compact papilloma-
virus genomes. The insertion of a translational termination
linker at position 2712 was enough to almost completely
inhibit splicing to the 2709 acceptor. The other E1-N TTL was
inserted at position 1311, and this resulted in a 1.6-fold
decrease in splicing of the 1302^3358 RNA species.
Mutations in specific DNA binding sites can also have
unexpected pleiotropic effects on binding of other factors. We
generated mutations in the E1 binding sites in the replication
origin (E1BS2 and E1BS4), but these had no phenotype in any
of the transcriptional assays. However, it has been shown that
the cellular CDP repressor (CAAAT displacement factor)
binds to sites that overlap with the E1 binding sites (O'Connor
et al., 2000). Therefore, great care must be taken in genetic
analysis of such mutations.
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sites 1 and 2 displaces TFIID and Sp1, respectively (Dong et al.,
1994; Tan et al., 1992; Demeret et al., 1997), and these sites play
an important role in transcriptional repression of P97 (Demeret
et al., 1997; Romanczuk et al., 1990). However, as discussed
above, DNA binding is not sufficient for repression and
interaction of E2 with other factors is also most likely involved.
We also find that binding sites 1 and 2 are important for
transcriptional repression. Mutation of site 3 alone does not
have a dramatic effect on HPV transcription but when mutated
in combination with sites 1 and/or 2 results in further alleviation
of repression.
Previous studies have shown an E2-mediated increase in
transcription when all three proximal binding sites were
mutated (E2BS1, 2, and 3), and this led to the proposal that
E2BS4 is involved in activation of transcription (Demeret et al.,
1997; Romanczuk et al., 1990; Steger and Corbach, 1997).
When all three proximal binding sites are mutated in the pEP
vector (pEP-4xxx), we see a substantial increase in transcription
of the HPVearly region. The additional expression of excess E2
further increases transcription but this increase is not dramatic
(Fig. 7). When only binding site 4 is mutated in pEP-x321, there
is no change in expression of the HPV early region. Expression
of excess E2 represses this construct slightly more than the
wild-type construct. Together, these results could indicate that
transcription of the HPV early region can be activated by
interaction of E2 with binding site 4. However, the contribution
of this activation is quite modest, and it appears that the overall
balance of E2 activity results in repression. Nevertheless,
binding site 4 is well conserved among the HPVs, which
indicates that it does play an important role at some point in the
viral life cycle.
In addition to providing insight into E2-mediated regula-
tion of transcription of the HPV16 early region in human
keratinocytes, this study provides an extensive and quantita-
tive analysis of the relative abundance of HPV16 transcripts.
HPV RNA species have been isolated by cDNA cloning and
RNAse protection studies, but a comprehensive analysis of
the relative abundance of each message has not previously
been presented. The E6*I and E7 messages are quite
abundant, being present at approximately 50,000 copies per
50 ng RNA sample, which we approximate originates from
5000 cells. The 880^3858 transcript (which could encode the
E1^E4 or E5 proteins) is also abundant and present at about
130,000 copies per 50 ng RNA. In contrast, transcripts that
express both full-length and truncated E2 species are
relatively rare. The 880^2709 and E8^E2C species are
present at about 10,000 and 2000 copies per sample,
respectively. The 880^2582 mRNA is extremely low at
about 100 copies per 50 ng RNA.
In summary, we demonstrate that the HPV16 E2 protein is
primarily a transcriptional repressor when expressed from the
background of the viral genome in human keratinocytes.
Furthermore, E2-mediated repression requires both the trans-
activation function of E2 and specific binding of the E2 protein
to sites in the LCR. We find no evidence that the E1 protein
directly modulates HPV16 gene expression. The knowledgeobtained from these studies will be invaluable in designing
strategies to intervene in the viral life cycle and lead to treatment
of papillomavirus associated diseases, such as cervical cancer.
Interfering with E1 function or the replication function of E2
should result in curing of viral genomes without a concomitant
increase in E6/E7 gene expression. However, abrogation of the
E2 DNA binding or transcriptional regulatory functions could




Plasmid pEP8 was created from pREP8 (Invitrogen) by
deletion of the BamHI-NruI fragment (nucleotides 406–864)
containing the RSV promoter. To avoid putative mutations
present in the prototype HPV16 clone, the HPV16 genome
derived from the episomal W12-E cell line (pEFHPV16W12E,
gift from Paul Lambert) was used as a source of HPV16
DNA. pEP16 was created by replacing the BamHI to NruI
fragment of pREP8 with the BamHI to XmnI fragment
containing early region of HPV16 (nucleotides 6150–4818)
from pEFHPV16W12E. pEP16E2-N and pEP16E1-C were
derived from pEFHPV16W12E by insertion of a translation
termination linker (TTL, TTTAGTTAACTAA) at the PflMI
(nt 2926) or TthIII I (nt 2712) sites, respectively. pEP16M is
very similar to pEP16 except that it has an XhoI linker at the
NruI site (nt 864) of pREP8 to allow the BamHI and XhoI
fragment of HPV16 (nt 6150–4818) to be inserted more
easily. All other mutations are in this background. pEP16E1-N
was generated by replacing the Asp718 and TthIII I fragment
of pEP16M with the same fragment from p16-Nt, which
contains a TTL at position 1311 (Romanczuk and Howley,
1992). Point mutations were introduced into either E1 or E2
genes by site-directed mutagenesis of intermediate plasmids
using appropriate oligonucleotide primers and the Transformer
site-directed mutagenesis kit (BD Biosciences Clontech). The
primers were designed to mutate the residues E39 in the E2
protein and K230, S231, and K483 residues in the E1 protein
to alanine by changing each target codon to GCA. Residues
R37 and I73 in E2 were also mutated to alanine by designing
the primer to change each target codon to GCC or GCT,
respectively. Residues R302 and R304 in E2 were substituted
to lysine by changing each target codon to AAA. The E1
binding sites mutations in LCR, E1BSM2 and E1BSM4, were
generated by using primers, AM829 (5′-caagcaacttatataaCaa-
tactaaactCcaataattcatgtataaaactaagggcg-3′, nt 7880–32) and
AM830 (5′-catttacaagcaacttatataaCaaCactaaactCcaCtaattcatg-
tataaaactaagggcg-3′, nt 7874–32), respectively. Mutations are
presented in upper case letters. Mutated regions containing
either the E1 or E2 genes or LCR were excised from
intermediate plasmids by either Asp718/XhoI or BamHI/
Asp718 digestion, respectively, and were subcloned into
pEP16M. Mutations were confirmed by sequencing. pEP16-
432x, -43xx, and -4xxx were created by inserting the KpnI
and BamHI fragment from p16-Lx, -Lxx, and -Lxxx,
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mutations, pEP16-43x1, -4x21, -4xx1, and -4x2x, the LCR
fragments containing -43x1, -4x21, -4xx1, and -4x2x muta-
tions were amplified by PCR from p16P-43x1, -4x21, -4xx1,
and -4x2x (Romanczuk et al., 1990) using primers, AM1053
and AM1054, respectively. The forward primer has the
sequence 5′-tcggttgcatgctttttgg-3′ (nt 7458–7466) containing
the SphI site (nt 7468). The reverse primer 5′-cctgtgggtcctgaa-
acattgcagttctcttttggtgc-3′ (nt 122–85) contains the PpuMI site
(nt 112). The PCR amplified product was digested with SphI
and PpuMI and then inserted into same sites of intermediate
plasmids. The Asp718 and BamHI fragments from these
intermediate plasmids were cloned into the same sites of
pEP16M. For pEP16-x321, an Asp718-BamHI fragment
containing nucleotides 6147 to 7475 was generated by PCR
amplification using primers containing a mutation in E2
binding site 4. The primers used were (5′-aaaggatccccatgtac-
caatg-3′, nt 6147–6168) and (5′-caaaaagcatgcaaAAgaattcgg-
3′, nt 7475–7452). Mutated nucleotides are in uppercase
letters. A few mutations that were discovered in the original
plasmids were corrected using QuikChange II (Stratagene).
Plasmids p16P-43x1 and -4xx1 contained a single base
deletion at nt 7771 and p16P-4x21 contained a single base
deletion at nt 7855. In p16-Lxx, nucleotide 7832 was mutated
from G to A and in p16P-43x1 nucleotide 90 was mutated
from A to C. All of these changes were corrected to the
sequence of the W12 and HPV16R genomes.
Plasmids used for standard curves for real-time PCR, p3331
and p3345, are 5′ RACE clones from W12 in pCRII-TOPO.
p3331 contains HPV16 sequences 95–226^409–880^3358–
3475, and p3345 contains HPV16 sequences 91–226^526–
880^3358–3475 (where ^ indicates splice and—indicates exon).
p2703, p2704, p2705, and p2706 plasmids were generated by
gene synthesis to contain E2 splice junction and contain se-
quences 866–880^2709–2778, 866–880^3358–3440, 1281–
1302^3358–3418, and 864–880^2582–2706 respectively.
Cell culture and transfection
Primary human foreskin keratinocytes (HFKs) were
isolated from neonatal foreskins and grown in F medium
[3:1 (v/v) F-12 Nutrient Mixture (Ham)-DMEM, 5% FBS,
0.4 μg/ml hydrocortisone, 5 μg/ml insulin, 8.4 ng/ml cholera
toxin, 10 ng/ml EGF, and 24 μg/ml adenine] (Jeon et al.,
1995) in the presence of irradiated 3T3 m1 feeder cells. One to
two days before transfection, 1 × 106 HFKs were plated in a
10-cm dish with keratinocyte-SFM (Invitrogen Corporation).
HFKs were transfected with 3 μg of DNA using FuGENE 6
(Roche), as specified by the manufacturer. For short-term
assays, cells were maintained in keratinocyte-SFM until
harvest. For long-term assays, cells containing the pEP
plasmids were continually selected for by culturing cells in
histidine-free F medium containing 0.8 mM histidinol in the
presence of irradiated 3T3 m1 feeder cells. The cervical
keratinocyte cell line W12 was grown in F medium in the
presence of irradiated 3T3 m1 cells (Jeon et al., 1995). Caski
cells were grown in DMEM/10% FBS.RNA preparation
Two days after transfection, total RNAwas isolated using the
RNAqueous Kit (Ambion Inc.). The RNAwas quantified using
the RiboGreen RNA Quantitation Kit (Molecular Probes) and
then treated with DNase I using DNAfree (Ambion Inc.). The
integrity of RNA samples was examined using the Bioanalyzer
2100 (Agilent Technologies). RNA prepared from keratinocytes
transduced with the pLXSN 16E6E7 retrovirus was a gift from
Baojin Fu and has been described previously (Fu et al., 2003).
RNA prepared from 293 cells transiently transfected with
plasmid SV40 P/E HPV16 (p1059), which contains HPV-16 nt
79–4468 positioned downstream of the SV40 early promoter
and expresses the entire early region of HPV-16 (Phelps et al.,
1988), was a gift from Michael Patrick.
Real-time QRT-PCR
Reverse transcriptase reactions were carried out using the
cDNA Archive Kit (PE Applied Biosystems). Real-time QRT-
PCR was performed using the ABI Prism 7900HT Sequence
Detector (PE Applied Biosystems) and SYBR Green PCR
Master Mix (Applied Biosystems). All reactions were run in
triplicate. Each reaction contained 12.5 μl of SYBR Green PCR
Master Mix, cDNA from 50 ng of RNA and 0.3 μM each
oligonucleotide primer in total volume of 25 μl. For detection of
histidinol dehydrogenase gene expression, cDNA from 0.5 ng
of RNAwas used. In each run, a triplicate 10-fold dilution series
(10 pg–0.1 fg) of either pEP16M, p3331, p3345, p2703, p2704,
p2705, and p2706 plasmids was included to generate a standard
curve of threshold cycle (Ct) versus log10 quantity (fg). The
sequences of primers are shown in Table 1. PCR was performed
at 95 °C for 10 min, followed by 40 cycles of denaturation at
95 °C for 10 s and annealing and extension at 60 °C for 60 s.
The specificity of each primer pair was determined by
dissociation curve analysis. The data were analyzed with SDS
2.1 software (Applied Biosystems).
For each sample, the amount of the target and histidinol
dehydrogenase transcripts was determined from the appropriate
standard curve. Values were adjusted for transfection efficiency
by measuring the level of histidinol dehydrogenase gene
expression and adjusting the values appropriately. Values
were converted to copy number and standardized across
experiments. Thus, transcript copy numbers can be directly
compared among the experiments presented.
DNA replication assay
The day before transfection, HFKs (6 × 105 cells) were plated
in a 100-mm dish in the presence of feeders as described above.
HFKs were transfected with 10 μg of DNA using Superfect
(QIAGEN), as specified by the manufacturer. Cells were
selected with 0.8 mM histidinol as described above. Twenty-
two days later, low molecular weight DNA was isolated by a
modified Hirt extraction procedure (Ustav and Stenlund, 1991).
Hirt extracted DNA samples were digested with DpnI and then
diluted 1:100 with TE. Replication of input DNAwas quantified
40 E. Soeda et al. / Virology 351 (2006) 29–41by real-time PCR, as previously described (Baxter andMcBride,
2005) using AM866 (nt 3459–3479, 5′-agacgactatccagcgaccaa-
3′) and AM867 (nt 3581–3558, 5′-tgtgtgagctgttaaatgcagtga-3′).
The amplicon contained one DpnI site (nt 3481).
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